KAEL-GemVax – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “KAEL-GemVax – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “KAEL-GemVax – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- KAEL-GemVax – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of KAEL-GemVax human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of KAEL-GemVax with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the KAEL-GemVax’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate KAEL-GemVax’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of KAEL-GemVax in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the KAEL-GemVax’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with KAEL-GemVax.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of KAEL-GemVax and identify potential opportunities in those areas.
KAEL-GemVax Snapshot
KAEL-GemVax Overview
Key Information
Key Facts
KAEL-GemVax – Research and Development Overview
Key Therapeutic Areas
KAEL-GemVax – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
KAEL-GemVax – Pipeline Products Glance
KAEL-GemVax – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
KAEL-GemVax Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
KAEL-GemVax – Drug Profiles
GV1001
Product Description
Mechanism of Action
R&D Progress
GV1001
Product Description
Mechanism of Action
R&D Progress
KAEL-GemVax – Pipeline Products by Route of Administration
KAEL-GemVax – Pipeline Products by Molecule Type
KAEL-GemVax – Locations And Subsidiaries
Head Office
Recent Developments
Jul 12, 2010: KAEL-GemVax Reports Significant Interim Progress In Phase III TeloVac Study Of GV1001 For Pancreatic Cancer
Mar 17, 2008: Onyvax European Phase IIB Clinical Trial Completes Enrolment
Dec 04, 2007: Onyvax Granted Broad Us Patent For Lead Prostate Cancer Vaccine
Sep 26, 2007: Phase IIB Clinical Trial Of Onyvax-P In Early Stage Prostate Cancer Initiated In United States
Dec 11, 2006: Onyvax Phase IIb Clinical Trial Of Prostate Cancer Vaccine Underway With The Addition Of UK Clinical Centres
Jun 17, 2005: Onyvax Publishes Results Of Phase II Prostate Cancer Vaccine Showing Significant Steps Towards Delaying Disease Progression
May 16, 2005: Onyvax-P May Significantly Extend Progression Free Survival Of Metastatic Prostate Cancer Patients
Feb 21, 2005: Onyvax US Clinical Advisory Board Reviews Phase II Data And Gives Input To Onyvax-P Late-Stage Clinical Trial Design In Prostate Cancer
Jun 17, 2004: Final Phase II Data Shows That Onyvax-P May Significantly Extend Progression Free Survival For Men With Advanced Prostate Cancer
Sep 24, 2003: Berna Biotech And Onyvax Announce Collaboration For Phase III Clinical Trials Of Onyvax-P
Financial Deals Landscape
KAEL-GemVax, Deals Summary, 2004 to 2010
KAEL-GemVax Detailed Deal Summary
Acquisition
KAEL Acquires Gemvax
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 26
LIST OF TABLES
KAEL-GemVax – Pipeline by Therapy Area and Indication, 2010
KAEL-GemVax – Pipeline by Stage of Development, 2010
KAEL-GemVax – Monotherapy Products in Pipeline, 2010
KAEL-GemVax – Phase III, 2010
KAEL-GemVax - Phase II, 2010
KAEL-GemVax – Pipeline By Route of Administration, 2010
KAEL-GemVax – Pipeline By Molecule Type, 2010
KAEL-GemVax, Deals Summary, 2004 to 2010 23
LIST OF FIGURES
KAEL-GemVax – Pipeline by Therapy Area and Indication, 2010
KAEL-GemVax – Pipeline by Stage of Development, 2010
KAEL-GemVax – Monotherapy Products in Pipeline, 2010 8
KAEL-GemVax Overview
Key Information
Key Facts
KAEL-GemVax – Research and Development Overview
Key Therapeutic Areas
KAEL-GemVax – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
KAEL-GemVax – Pipeline Products Glance
KAEL-GemVax – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
KAEL-GemVax Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
KAEL-GemVax – Drug Profiles
GV1001
Product Description
Mechanism of Action
R&D Progress
GV1001
Product Description
Mechanism of Action
R&D Progress
KAEL-GemVax – Pipeline Products by Route of Administration
KAEL-GemVax – Pipeline Products by Molecule Type
KAEL-GemVax – Locations And Subsidiaries
Head Office
Recent Developments
Jul 12, 2010: KAEL-GemVax Reports Significant Interim Progress In Phase III TeloVac Study Of GV1001 For Pancreatic Cancer
Mar 17, 2008: Onyvax European Phase IIB Clinical Trial Completes Enrolment
Dec 04, 2007: Onyvax Granted Broad Us Patent For Lead Prostate Cancer Vaccine
Sep 26, 2007: Phase IIB Clinical Trial Of Onyvax-P In Early Stage Prostate Cancer Initiated In United States
Dec 11, 2006: Onyvax Phase IIb Clinical Trial Of Prostate Cancer Vaccine Underway With The Addition Of UK Clinical Centres
Jun 17, 2005: Onyvax Publishes Results Of Phase II Prostate Cancer Vaccine Showing Significant Steps Towards Delaying Disease Progression
May 16, 2005: Onyvax-P May Significantly Extend Progression Free Survival Of Metastatic Prostate Cancer Patients
Feb 21, 2005: Onyvax US Clinical Advisory Board Reviews Phase II Data And Gives Input To Onyvax-P Late-Stage Clinical Trial Design In Prostate Cancer
Jun 17, 2004: Final Phase II Data Shows That Onyvax-P May Significantly Extend Progression Free Survival For Men With Advanced Prostate Cancer
Sep 24, 2003: Berna Biotech And Onyvax Announce Collaboration For Phase III Clinical Trials Of Onyvax-P
Financial Deals Landscape
KAEL-GemVax, Deals Summary, 2004 to 2010
KAEL-GemVax Detailed Deal Summary
Acquisition
KAEL Acquires Gemvax
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 26
LIST OF TABLES
KAEL-GemVax – Pipeline by Therapy Area and Indication, 2010
KAEL-GemVax – Pipeline by Stage of Development, 2010
KAEL-GemVax – Monotherapy Products in Pipeline, 2010
KAEL-GemVax – Phase III, 2010
KAEL-GemVax - Phase II, 2010
KAEL-GemVax – Pipeline By Route of Administration, 2010
KAEL-GemVax – Pipeline By Molecule Type, 2010
KAEL-GemVax, Deals Summary, 2004 to 2010 23
LIST OF FIGURES
KAEL-GemVax – Pipeline by Therapy Area and Indication, 2010
KAEL-GemVax – Pipeline by Stage of Development, 2010
KAEL-GemVax – Monotherapy Products in Pipeline, 2010 8
